华峰制药品牌怎么样 申请店铺

我要投票 华峰制药在医疗器械行业中的票数:95 更新时间:2025-02-24
华峰制药是哪个国家的品牌?「华峰制药」是 河南华峰制药有限公司 旗下著名品牌。该品牌发源于河南省濮阳市,由创始人娄 *在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华峰制药品牌出海!通过在本页面挂载华峰制药品牌的产品链接和联系邮箱,可以提高华峰制药产品曝光!跨境电商爆单神器,目前只要100元/年哦~

华峰制药怎么样

河南华峰制药有限公司是2000年5月经国家有关部委批准成立的股份制企业,现有资产5000万元, 厂区占地面积3万平方米,建筑面积2万平方米,占地62亩的二期工程正在筹建中。公司拥有各类高、中级技术人员200余人,专业营销人员100余人。公司地处园林城、卫生城、文明城、旅游城濮阳市高新技术产业开发区。西有濮阳的绿色庄园、濮上园等城市标志性旅游景点,东临南北走向的城市绿化森林,环境幽雅,交通便利 。

河南华峰制药有限公司以开发治疗骨病系列药品为主,承担着国家治疗骨病骨伤研发药品的项目,目前拥有生产国药准字号丸剂、酒剂及膏药等六个剂型共20多个品种, 形成了具有传统中医药生产销售与临床推广为一体的经营新格局,公司以开发骨病治疗药品为主,承担着国家治疗骨病研究的项目,公司自行研制生产的“娄峰”牌正骨膏、治伤消瘀丸、风湿骨病丸、祛风湿膏、骨痛药酒等,以其品质及适应性赢得了广大用户的认可,在医院专科专病建设领域树立了品牌。公司产品市场销售及医疗服务网络涉及东北地区、北京、山东、山西、安徽、江苏、上海等省市700多家医疗单位,创出了一条医疗服务和药品销售相结合的经营新模式,形成了区域拓展广阔的销售网络。

华峰公司将发展领域定位于人类健康产业,即中医药产业。专注于骨科病等病症的名优中成药,实施名牌战略,中药现代化和产业化的接轨,高度重视以市场为导向,具有前沿技术的研发能力的培育,完善以顾客为导向的营销战略,保障在行业中保持优势的竞争地位。华峰核心竞争力源于企业核心技术能力、应变能力、组织协调能力和企业影响力。华峰注重企业文化的建设借以形成能力出众、卓识创新的人才群体,打造高水准的华峰营销模式,不断改进华峰的管理和生产模式,提高华峰品质,以形成华峰的市场竞争力。

进入新世纪,经济全球化、全球信息化、知识经济新时代已经来临,它对公司现有的生产方式、生活方式、思维方式、管理方式等都将产生重大影响,必将引发企业管理上的新一轮创新性的革命。华峰全体员工将认清形势,持续不断地开展观念创新、知识创新、管理创新、市场创新、机制创新、技术创新、质量创新、产品创新,以求真、务实、创新的精神和干劲,保持企业稳健、持续发展,做行业先锋,创世纪品牌。

成熟的技术,优良的设备,科学的管理,使河南华峰制药有限公司成为研发与生产治疗骨病系列药品的优势企业,在全国地区的中药制药现代化进程中焕发出无限生机。


Henan Huafeng Pharmaceutical Co., Ltd. is a joint-stock enterprise established in May 2000 with the approval of the relevant ministries and commissions of the state. The current assets are 50 million yuan, the plant covers an area of 30000 square meters, the building area is 20000 square meters, and the second phase project covering 62 Mu is under preparation. The company has more than 200 high and intermediate technical personnel and more than 100 professional marketing personnel. The company is located in the park city, health city, civilization city, tourism city Puyang high tech Industrial Development Zone. In the west, there are the Green Manor of Puyang, the park of pushangyuan and other urban landmark tourist attractions. In the East, there is the North-South urban green forest, with elegant environment and convenient transportation. Henan Huafeng Pharmaceutical Co., Ltd. is mainly engaged in the development of a series of drugs for the treatment of osteopathy, and undertakes the national research and development of drugs for the treatment of osteopathy and osteopathy. At present, it has produced more than 20 varieties of six dosage forms, such as Guoyao Zhun brand pills, liquors and plasters, forming a new business pattern with the integration of traditional Chinese medicine production and sales and clinical promotion. The company focuses on the development of drugs for the treatment of osteopathy The company has undertaken the national research project of bone disease treatment. The company has developed and produced "Loufeng" brand bone paste, zhishangxiaoyu pill, Fengshi bone disease pill, Qufengshi ointment, bone pain medicine liquor, etc., which have won the recognition of the majority of users for their quality and adaptability, and established a brand in the field of hospital specialized disease construction. The company's product market sales and medical service network involve more than 700 medical units in Northeast China, Beijing, Shandong, Shanxi, Anhui, Jiangsu, Shanghai and other provinces and cities. It has created a new business model combining medical service and drug sales, and formed a wide regional sales network. Huafeng company will focus on the development of human health industry, that is, traditional Chinese medicine industry. Focus on famous and excellent Chinese patent medicines for orthopedic diseases, implement the famous brand strategy, integrate the modernization and industrialization of traditional Chinese medicine, attach great importance to the cultivation of market-oriented, cutting-edge technology research and development ability, improve customer-oriented marketing strategy, and ensure the competitive position in the industry. The core competitiveness of Huafeng comes from the core technology ability, adaptability, organization and coordination ability and enterprise influence. Huafeng attaches great importance to the construction of corporate culture so as to form a talent group with outstanding ability and outstanding innovation, build a high-level marketing mode, constantly improve the management and production mode of Huafeng, improve the quality of Huafeng, and form the market competitiveness of Huafeng. In the new century, the new era of economic globalization, global information and knowledge economy has come. It will have a significant impact on the company's existing production mode, life style, thinking mode, management mode, etc., and will inevitably lead to a new round of innovative revolution in enterprise management. All staff of Huafeng will recognize the situation, continuously carry out concept innovation, knowledge innovation, management innovation, market innovation, mechanism innovation, technology innovation, quality innovation and product innovation, keep the enterprise steady and sustainable development, be the industry leader and create century brand with the spirit and drive of truth-seeking, pragmatic and innovation. With mature technology, excellent equipment and scientific management, Henan Huafeng Pharmaceutical Co., Ltd. has become an advantageous enterprise in R & D and production of series drugs for treating bone disease, which is full of infinite vitality in the process of modernization of traditional Chinese medicine in the whole country.

本文链接: https://brand.waitui.com/e4731c9c9.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

2小时前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

2小时前

山河药辅:股东复星医药拟减持不超过3%公司股份

36氪获悉,山河药辅发布公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

2小时前

镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布

36氪获悉,近日镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布。作为镁伽在“AI for Science(AI4S)”领域的新成果,LABILLION™以AI与自动化技术为核心,针对生命科学研发中长期存在的数据孤岛、系统僵化、流程低效等痛点,为科学家提供从实验设计到数据分析的全链路智能支持,助力科研创新效率的提升。

2小时前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询